Home
TrialNet

TrialNet Market Share Analysis for November 2025

Health > Health Conditions and Concerns

Domaintrialnet.org

Year Founded--

Employees51 - 200

Annual Revenue$15M - $25M

TrialNet

TrialNet (including company regionals)

trialnet.org

See more website traffic and engagement information

TrialNet Revenue up to November 2025 is 15M - 25M

revenue generated by TrialNet top domains

TrialNet top domains revenue over 3 years

Revenue for TrialNet top domains

trialnet.org15M - 25M

See more with Sales Intelligence

Total visits to TrialNet's top domains

Understand TrialNet market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

trialnet.org14.6K

See more with Sales Intelligence

Avg. visit duration in TrialNet's top domains

Analyze TrialNet engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

trialnet.org00:00:34

See more with Sales Intelligence

Avg. pageviews on TrialNet's top domains

See how TrialNet keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

trialnet.org2.86

See more with Sales Intelligence

TrialNet top competitors by domain

Top similar sites in November 2025, ranked by their affinity

breakthrought1d.orgCompany NameBreakthrough T1DEmployees501 - 1000HQUnited States, New York, New YorkAnnual revenue--Total visits154.2KHealth > Health Conditions and Concerns

Top technologies used by TrialNet

These are the website technologies, by industry, used by TrialNet top domains

Advertising (4)

DoubleClick

Social (4)

Instagram

Content Management System (3)

Drupal

Widget (3)

reCAPTCHA

More Technologies

9

See all

News & Signals from TrialNet

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNektar Therapeutics partners with TrialNet.Additionally, Nektar has partnered with TrialNet to conduct a Phase 2 study of rezpegaldesleukin in stage 3 type 1 diabetes patients, focusing on the drug's safety and potential efficacy.

NewsTrialNet launched JAKPOT T1D on Nov 7th '23.Last month, type 1 diabetes research network TrialNet launched a study called JAKPOT T1D that is testing two other JAK inhibitors - Pfizer's Cibinqo (abrocitinib) and Litfulo (ritlecitinib) - to see if they can preserve insulin function in newly diagnosed patients.

NewsTrialNet hires Carla J. Greenbaum as chair.Carla J. Greenbaum, MD, has been named chair of Type 1 Diabetes TrialNet, the National Institutes of Health (NIH) funded clinical trial network for type 1 diabetes prevention and early treatment.